174 related articles for article (PubMed ID: 27470571)
81. Acquired platinum resistance enhances tumour angiogenesis through angiotensin II type 1 receptor in bladder cancer.
Tanaka N; Miyajima A; Kosaka T; Miyazaki Y; Shirotake S; Shirakawa H; Kikuchi E; Oya M
Br J Cancer; 2011 Oct; 105(9):1331-7. PubMed ID: 21970881
[TBL] [Abstract][Full Text] [Related]
82. Candesartan targeting of angiotensin II type 1 receptor demonstrates benefits for hypertension in pregnancy via the NF‑κB signaling pathway.
Zhao X; Wang X
Mol Med Rep; 2018 Jul; 18(1):705-714. PubMed ID: 29845261
[TBL] [Abstract][Full Text] [Related]
83. Agrin Mediates Angiogenesis in the Tumor Microenvironment.
Chakraborty S; Njah K; Hong W
Trends Cancer; 2020 Feb; 6(2):81-85. PubMed ID: 32061308
[TBL] [Abstract][Full Text] [Related]
84. The Role of Angiogenesis in Hepatocellular Carcinoma.
Morse MA; Sun W; Kim R; He AR; Abada PB; Mynderse M; Finn RS
Clin Cancer Res; 2019 Feb; 25(3):912-920. PubMed ID: 30274981
[TBL] [Abstract][Full Text] [Related]
85. Angiotensin II receptor type 1 blocker candesartan improves morphine tolerance by reducing morphine‑induced inflammatory response and cellular activation of BV2 cells via the PPARγ/AMPK signaling pathway.
Zhao W; Shen F; Yao J; Su S; Zhao Z
Mol Med Rep; 2022 Oct; 26(4):. PubMed ID: 36004465
[TBL] [Abstract][Full Text] [Related]
86. Synergistic Suppression of Tumor Angiogenesis by the Co-delivering of Vascular Endothelial Growth Factor Targeted siRNA and Candesartan Mediated by Functionalized Carbon Nanovectors.
Ding X; Su Y; Wang C; Zhang F; Chen K; Wang Y; Li M; Wang W
ACS Appl Mater Interfaces; 2017 Jul; 9(28):23353-23369. PubMed ID: 28617574
[TBL] [Abstract][Full Text] [Related]
87. Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives.
Sun HC; Tang ZY
J Cancer Res Clin Oncol; 2004 Jun; 130(6):307-19. PubMed ID: 15034787
[TBL] [Abstract][Full Text] [Related]
88. Angiotensin II and tumor necrosis factor-α stimulate the growth, migration and invasion of BEL-7402 cells via down-regulation of GRK2 expression.
Xu ZW; Yan SX; Wu HX; Zhang Y; Wei W
Dig Liver Dis; 2019 Feb; 51(2):263-274. PubMed ID: 30712649
[TBL] [Abstract][Full Text] [Related]
89. HM-3-HSA exhibits potent anti-angiogenesis and antitumor activity in hepatocellular carcinoma.
Li T; Ge G; Zhang H; Wang R; Liu Y; Zhang Q; Yue Z; Ma W; Li W; Zhang J; Yang H; Wang P; Zhao J; Fang Y; Xie Q; Wang M; Li Y; Zhu H; Li H
Eur J Pharm Sci; 2021 Dec; 167():106017. PubMed ID: 34555448
[TBL] [Abstract][Full Text] [Related]
90. The ubiquitin-like protein FAT10 in hepatocellular carcinoma cells limits the efficacy of anti-VEGF therapy.
Qiu Y; Che B; Zhang W; Zhang AV; Ge J; Du D; Li J; Peng X; Shao J
J Adv Res; 2024 May; 59():97-109. PubMed ID: 37328057
[TBL] [Abstract][Full Text] [Related]
91. Exploring the role of the membrane bilayer in the recognition of candesartan by its GPCR AT1 receptor.
Kiriakidi S; Chatzigiannis C; Papaemmanouil C; Tzakos AG; Mavromoustakos T
Biochim Biophys Acta Biomembr; 2020 Mar; 1862(3):183142. PubMed ID: 31830465
[TBL] [Abstract][Full Text] [Related]
92. Sorafenib inhibits growth of hepatoma with hypoxia and hypoxia-driven angiogenesis in nude mice.
Li F; Wang F; Wu J
Neoplasma; 2017; 64(5):718-724. PubMed ID: 28592123
[TBL] [Abstract][Full Text] [Related]
93. Aptamer-functionalized peptide H3CR5C as a novel nanovehicle for codelivery of fasudil and miRNA-195 targeting hepatocellular carcinoma.
Liu Y; Wu X; Gao Y; Zhang J; Zhang D; Gu S; Zhu G; Liu G; Li X
Int J Nanomedicine; 2016; 11():3891-905. PubMed ID: 27574422
[TBL] [Abstract][Full Text] [Related]
94. Tumor angiogenesis and its clinical significance in pediatric malignant liver tumor.
Sun XY; Wu ZD; Liao XF; Yuan JY
World J Gastroenterol; 2005 Feb; 11(5):741-3. PubMed ID: 15655835
[TBL] [Abstract][Full Text] [Related]
95. Candesartan induces a prolonged proangiogenic effect and augments endothelium-mediated neuroprotection after oxygen and glucose deprivation: role of vascular endothelial growth factors A and B.
Soliman S; Ishrat T; Pillai A; Somanath PR; Ergul A; El-Remessy AB; Fagan SC
J Pharmacol Exp Ther; 2014 Jun; 349(3):444-57. PubMed ID: 24681872
[TBL] [Abstract][Full Text] [Related]
96. Nogo-B promotes tumor angiogenesis and provides a potential therapeutic target in hepatocellular carcinoma.
Cai H; Saiyin H; Liu X; Han D; Ji G; Qin B; Zuo J; Shen S; Yu W; Wu J; Wu Y; Yu L
Mol Oncol; 2018 Dec; 12(12):2042-2054. PubMed ID: 30019429
[TBL] [Abstract][Full Text] [Related]
97. Oxyresveratrol prevents murine H22 hepatocellular carcinoma growth and lymph node metastasis via inhibiting tumor angiogenesis and lymphangiogenesis.
Liu Y; Ren W; Bai Y; Wan L; Sun X; Liu Y; Xiong W; Zhang YY; Zhou L
J Nat Med; 2018 Mar; 72(2):481-492. PubMed ID: 29350326
[TBL] [Abstract][Full Text] [Related]
98. Candesartan ameliorates vascular smooth muscle cell proliferation via regulating miR-301b/STAT3 axis.
Zhang L; Yang F; Yan Q
Hum Cell; 2020 Jul; 33(3):528-536. PubMed ID: 32170715
[TBL] [Abstract][Full Text] [Related]
99. Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice.
Zhang ZL; Liu ZS; Sun Q
World J Gastroenterol; 2005 Jan; 11(2):216-20. PubMed ID: 15633219
[TBL] [Abstract][Full Text] [Related]
100. Angiotensin-converting enzyme inhibitors have adverse effects in anti-angiogenesis therapy for hepatocellular carcinoma.
Zhang S; Cao M; Hou Z; Gu X; Chen Y; Chen L; Luo Y; Chen L; Liu D; Zhou H; Zhu K; Wang Z; Zhang X; Zhu X; Cui Y; Li H; Guo H; Zhang T
Cancer Lett; 2021 Mar; 501():147-161. PubMed ID: 33383154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
